Illumina, Inc. announced on 15 May that it acquired Edico Genome, the leading provider of data analysis acceleration solutions for next-generation sequencing (NGS).

Edico Genome’s DRAGEN® Bio-IT Platform (DRAGEN) uses field programmable gate array (FPGA) technology in conjunction with proprietary software algorithms to reduce both data footprint and time to results.

DRAGEN can be run on premise, in the cloud, or in a hybrid mode, and is flexible and compatible for use with multiple cloud storage solutions and analysis pipelines. Edico Genome has built a strong base of NGS customers who have incorporated DRAGEN as a standard part of their sequencing workflow.

“Thanks to Illumina, the ability to generate accurate and affordable sequencing data is rapidly expanding the market and use cases for NGS. As the scale of sequencing expands, decreasing the cost and time of analysis will be important to fuel the clinical adoption of sequencing,” said Pieter van Rooyen PhD, President and CEO of Edico Genome. “Our team is invigorated at the prospect of joining Illumina to combine our respective strengths to streamline and accelerate secondary analysis for the genomics community.”

Source: Illumina, edited